Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease

NCT00136396 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Graft vs Host Disease

Interventions

DRUG: Rituximab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]